Laura Borsi;Christoph-Stephan Hilger;Barbara Carnemolla;Patrizia Castellani;Luciano Zardi;Matthias Friebe;Enrica Balza
发明人:
Laura Borsi,Barbara Carnemolla,Enrica Balza,Patrizia Castellani,Luciano Zardi,Matthias Friebe,Christoph-Stephan Hilger
申请号：
US10507178
公开号：
US08491906B2
申请日:
2003.03.11
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The present invention relates to selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19, to the angiogenesis marker ED-B domain of fibronectin. In preferred embodiments, a complete human IgG1 is employed having the variable regions of L19. In other preferred embodiments is employed a mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4 domain of a secretory IgE isoform that naturally contains a cysteine in its COOH terminal and which forms a covalently linked dimer. Different in vivo behavior of the antibody formats is exploitable for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. The antibody molecules may be labelled as described.
